World Orphan Drug Congress Focuses on Patients

World Orphan Drug Congress Focuses on Patients

For those of us connected with manufacturing or managing orphan drugs, it's easy to obsess over the numbers:  there are 7,000 designated rare diseases, but fewer than 400 approved orphan drug therapies; more than 30 million Americans have been diagnosed with a rare disease, yet only one-third of those are receiving treatment.

But numbers are taking a backseat this week at the World Orphan Drug Congress being held in National Harbor, Maryland, where faculty and 300+ attendees are focused on one thing:  the patient.  Leaders from patient advocacy groups, pharmaceutical manufacturers, and governmental agencies agree that a patient-centered approach to orphan drug management is vital and that when all services are aligned around the patient, the best possible outcomes are sure to follow.

HealthBridge Pharma & Biotech has its own staggering number:  more than 90% of the drugs in our CuraScript Specialty Pharmacy are orphan or ultra orphan drugs.  We understand that small patient populations need big solutions and a little extra attention.  That's why we offer unique, patient-focused programs to support orphan drugs, and why we're proud to be collaborating at such an important event.

If you're attending the World Orphan Drug Congress, let's connect!  HealthBridgePharma&Biotech@express-scripts.com